Action Pharmala Biotech - MDMA

Pharmala Biotech Holdings Inc (MDMA) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,135

( -15,63% )

Prix Achat

0,13

Prix Vente

0,14

Volume échangé

249 324

0,135 Fourchette du Jour 0,165

0,085 Plage de 52 semaines 0,195

Cap du marché

14,7M

Clôture Veille

0,16

Ouverture

0,165

Dernière Transaction

1000

0.135

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

$ 205 922

Actions en circulation

108 887 215

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-10

Bénéfice par action (BPA)

-0,02

Chiffre d'affairess (LTM)

889,57k

Bénéfice net (LTM)

-1,63M

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headqu... Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. Show more

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

pharmala.ca

Siège social

Vancouver, Canada

Fondé

Pharmala Biotech Holdings Inc est coté dans le secteur Healthcare de la Canadian Securities Exchange avec le ticker MDMA. Le dernier cours de clôture d'Pharmala Biotech était de $0,16. Au cours de la dernière année, les actions de Pharmala Biotech ont été négociées dans une fourchette de prix de $ 0,085 à $ 0,195.

Pharmala Biotech compte actuellement 108 887 215 actions en circulation. La capitalisation boursière d'Pharmala Biotech est de $14,70 million. Pharmala Biotech a un ratio cours/bénéfice (ratio PE) de -10.00.

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF...

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President...

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF...

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

PharmAla Issues Q2 Financial Statements and Grants Options

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”...

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

Cortexa Advances Commercialisation of MDMA Supply in Australia

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading...

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.035	-20.5882352941	0.17	0.175	0.135	109086	0.16097815	CS
4	-0.01	-6.89655172414	0.145	0.195	0.135	162800	0.1604637	CS
12	0.025	22.7272727273	0.11	0.195	0.085	209900	0.15782705	CS
26	0.045	50	0.09	0.195	0.085	169402	0.13684427	CS
52	0.04	42.1052631579	0.095	0.195	0.085	179068	0.12607171	CS
156	-0.18	-57.1428571429	0.315	0.425	0.065	346526	0.19433106	CS
260	-0.305	-69.3181818182	0.44	0.54	0.02	443713	0.18487265	CS

MDMA - Frequently Asked Questions (FAQ)

What is the current Pharmala Biotech Holdings Inc share price?

The current share price of Pharmala Biotech Holdings Inc is $ 0,135

How many Pharmala Biotech Holdings Inc shares are in issue?

Pharmala Biotech Holdings Inc has 108 887 215 shares in issue

What is the market cap of Pharmala Biotech Holdings Inc?

The market capitalisation of Pharmala Biotech Holdings Inc is CAD 14,7M

What is the 1 year trading range for Pharmala Biotech Holdings Inc share price?

Pharmala Biotech Holdings Inc has traded in the range of $ 0,085 to $ 0,195 during the past year

What is the PE ratio of Pharmala Biotech Holdings Inc?

The price to earnings ratio of Pharmala Biotech Holdings Inc is -10

What is the cash to sales ratio of Pharmala Biotech Holdings Inc?

The cash to sales ratio of Pharmala Biotech Holdings Inc is 18,97

What is the registered address of Pharmala Biotech Holdings Inc?

The registered address for Pharmala Biotech Holdings Inc is 1055 West Georgia Street, Vancouver, British Columbia, V6E 4N7

What is the Pharmala Biotech Holdings Inc website address?

The website address for Pharmala Biotech Holdings Inc is pharmala.ca

Which industry sector does Pharmala Biotech Holdings Inc operate in?

Pharmala Biotech Holdings Inc operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharmala Biotech Holdings Inc (MDMA)

Pharmala Biotech Holdings Inc (MDMA) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Pharmala Biotech Holdings Inc

MDMA Dernières nouvelles

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

Cortexa Advances Commercialisation of MDMA Supply in Australia

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

Cortexa Advances Commercialisation of MDMA Supply in Australia

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

PharmAla Announces Changes to Board of Directors

PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research

MDMA - Frequently Asked Questions (FAQ)

MDMA Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités